Nature Medicine

Nature Medicine

Artificial intelligence aims to improve cancer screenings in Kenya

16-10-2019 – Nicole Wetsman

Retraction Note: The hidden cost of genetic resistance to HIV-1

08-10-2019 – Jeremy Luban

Published Erratum, Retraction of Publication

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Retraction Note: CCR5-∆32 is deleterious in the homozygous state in humans

08-10-2019 – Xinzhu Wei,Rasmus Nielsen

Published Erratum, Retraction of Publication

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

A clonal expression biomarker associates with lung cancer mortality

07-10-2019 – Dhruva Biswas,Nicolai J. Birkbak,Rachel Rosenthal,Crispin T. Hiley,Emilia L. Lim,Krisztian Papp,Stefan Boeing,Marcin Krzystanek,Dijana Djureinovic,Linnea La Fleur,Maria Greco,Balázs Döme,János Fillinger,Hans Brunnström,Yin Wu,David A. Moore,Marcin Skrzypski,Christopher Abbosh,Kevin Litchfield,Maise Al Bakir,Thomas B. K. Watkins,Selvaraju Veeriah,Gareth A. Wilson,Mariam Jamal-Hanjani,Judit Moldvay,Johan Botling,Arul M. Chinnaiyan,Patrick Micke,Allan Hackshaw,Jiri Bartek,Istvan Csabai,Zoltan Szallasi,Javier Herrero,Nicholas McGranahan,Charles Swanton

Journal Article

An aim of molecular biomarkers is to stratify patients with cancer into disease subtypes predictive of outcome, improving diagnostic precision beyond clinical descriptors such as tumor stage

Immunotherapy for heart injury

07-10-2019 – Hannah Stower

Journal Article

Microneedle patch drug delivery in the gut

07-10-2019 – Mark R. Prausnitz,Yasmine Gomaa,Wei Li

Journal Article

Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse

07-10-2019 – Francesca Chemi,Dominic G. Rothwell,Nicholas McGranahan,Sakshi Gulati,Chris Abbosh,Simon P. Pearce,Cong Zhou,Gareth A. Wilson,Mariam Jamal-Hanjani,Nicolai Birkbak,Jackie Pierce,Chang Sik Kim,Saba Ferdous,Deborah J. Burt,Daniel Slane-Tan,Fabio Gomes,David Moore,Rajesh Shah,Maise Al Bakir,Crispin Hiley,Selvaraju Veeriah,Yvonne Summers,Philip Crosbie,Sophia Ward,Barbara Mesquita,Marek Dynowski,Dhruva Biswas,Jonathan Tugwood,Fiona Blackhall,Crispin Miller,Allan Hackshaw,Ged Brady,Charles Swanton,Caroline Dive

Journal Article

Approximately 50% of patients with early-stage non-small-cell lung cancer (NSCLC) who undergo surgery with curative intent will relapse within 5 years

Genome-wide germline correlates of the epigenetic landscape of prostate cancer

07-10-2019 – Kathleen E. Houlahan,Yu-Jia Shiah,Alexander Gusev,Jiapei Yuan,Musaddeque Ahmed,Anamay Shetty,Susmita G. Ramanand,Cindy Q. Yao,Connor Bell,Edward O’Connor,Vincent Huang,Michael Fraser,Lawrence E. Heisler,Julie Livingstone,Takafumi N. Yamaguchi,Alexandre Rouette,Adrien Foucal,Shadrielle Melijah G. Espiritu,Ankit Sinha,Michelle Sam,Lee Timms,Jeremy Johns,Ada Wong,Alex Murison,Michèle Orain,Valérie Picard,Hélène Hovington,Alain Bergeron,Louis Lacombe,Mathieu Lupien,Yves Fradet,Bernard Têtu,John D. McPherson,Bogdan Pasaniuc,Thomas Kislinger,Melvin L. K. Chua,Mark M. Pomerantz,Theodorus van der Kwast,Matthew L. Freedman,Ram S. Mani,Housheng H. He,Robert G. Bristow,Paul C. Boutros

Journal Article

Oncogenesis is driven by germline, environmental and stochastic factors. It is unknown how these interact to produce the molecular phenotypes of tumors. We therefore quantified the influence of germline polymorphisms on the somatic epigenome of 589 localized prostate tumors. Predisposition risk loci influence a tumor’s epigenome, uncovering a mechanism for cancer susceptibility. We identified and validated 1,178 loci associated with altered methylation in tumoral but not nonmalignant tissue. These tumor methylation quantitative trait loci influence chromatin structure, as well as RNA and protein abundance. One prominent tumor methylation quantitative trait locus is associated with AKT1 expression and is predictive of relapse after definitive local therapy in both discovery and validation cohorts. These data reveal intricate crosstalk between the germ line and the epigenome of primary tumors, which may help identify germline biomarkers of aggressive disease to aid patient triage and optimize the use of more invasive or expensive diagnostic assays.